Protagenic Therapeutics, Inc. (NASDAQ:PTIX – Get Free Report)’s stock price fell 6.5% on Monday . The stock traded as low as $0.25 and last traded at $0.26. 86,433 shares were traded during trading, a decline of 86% from the average session volume of 637,944 shares. The stock had previously closed at $0.28.
Protagenic Therapeutics Stock Performance
The stock has a market cap of $1.89 million, a PE ratio of -0.21 and a beta of 0.43. The firm has a 50-day moving average price of $0.33 and a 200-day moving average price of $0.51.
Protagenic Therapeutics Company Profile
Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
Featured Articles
- Five stocks we like better than Protagenic Therapeutics
- Using the MarketBeat Dividend Yield Calculator
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- Insider Trading – What You Need to Know
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
